Research programme: infectious disease and cancer vaccines - Hookipa Biotech

Drug Profile

Research programme: infectious disease and cancer vaccines - Hookipa Biotech

Alternative Names: artLCMV - Hookipa; Genetic vaccines for infectious diseases and cancer - Hookipa Biotech; HB-201; Hb-301; HB-401; HB301

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hookipa Biotech
  • Class Cancer vaccines; Immunotherapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Viral infections

Most Recent Events

  • 17 Oct 2016 Preclinical development is ongoing in Austria for viral infections and cancer
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in Austria
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top